Inhalable dry powder formulations comprising angiogenesis inhibitors
AssigneeLonza Bend Inc.
InventorsKimberly Shepard, Michael Banks, David Vodak
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to inhalable dry powder formulations comprising one or more antibodies or one or more angiogenesis inhibiting active pharmaceutical ingredients, methods of manufacture of such compositions, e.g., via spray drying, as well as their local administration to the lung for use in the treatment, prevention and/or delay of progression of asthma, COPD, lung infections, cystic fibrosis, or lung cancer.
Claims20
A dry powder formulation suitable for administration via inhalation comprising one or more antibodies or one or more angiogenesis inhibitors, a small molecular API, a stabilizer, and a dispersant.
Dependencies are inferred from the claim text.